Quantcast

Latest Ranbaxy Laboratories Stories

2009-05-01 18:00:00

PRINCETON, N.J., May 1 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) announced today that it is conducting a voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, USP 100 mg currently on the market in the U.S. Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy decided to recall all the lots, as a matter of abundant caution, given its commitment to the health and safety of...

2009-04-02 09:20:02

The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures. The federal agency said prescribing information or labeling for generic topiramate will differ from the innovator drug, Topamax, because some uses of Topamax are protected by patents and exclusivity. The labeling for both Topamax and generic topiramate contain a safety warning about metabolic acidosis, a condition associated with excessive acid in the blood that...

2009-03-05 10:09:00

PRINCETON, N.J., March 5 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg. The Application for the drug was submitted by Ranbaxy, from its Ohm Laboratories manufacturing facility located in...

2009-02-25 14:23:00

GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner. The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with...

2009-02-25 11:19:38

The U.S. Food and Drug Administration says it is taking new regulatory action against Ranbaxy Pharmaceuticals Inc.'s Paonta Sahib plant in India. The FDA said it has halted the review of drug applications from the plant, accusing officials of falsifying data and test results in approved and pending drug applications. The facility has been under an FDA import alert since September. The federal agency said it is continuing to investigate this matter to ensure the safety and efficacy of marketed...

2008-11-11 00:00:27

Research and Markets (http://www.researchandmarkets.com/research/9681f0/india_pharmaceutic) has announced the addition of the "India Pharmaceutical Regulatory Report 2008 (with appendix)" report to their offering. The India Pharmaceutical Regulatory Report comprehensively covers all aspects of pharmaceutical regulations in India. It includes overviews of the laws and procedures on registration, manufacturing, distribution, price control, marketing, research and development, and...

2008-10-31 09:00:27

Research and Markets (http://www.researchandmarkets.com/research/45cca1/indian_pharmaceuti) has announced the addition of the "Indian Pharmaceutical Industry" report to their offering. The Indian pharmaceutical industry grew at 13% during 2003-2007, driven by rising consumption levels in the country and strong demands from export markets. In 2006-07, the Indian pharma market reached US 8.16 billion and is estimated to reach US 9.77 billion in 2007-08. At present, India's pharmaceutical...

2008-10-03 09:00:37

Research and Markets (http://www.researchandmarkets.com/research/6d2dfc/japan_pharmaceutic) has announced the addition of the "Japan Pharmaceuticals and Healthcare Report Q3 2008" report to their offering. BMI's Japan Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Japan's pharmaceuticals and healthcare industry. Japan has the second largest pharmaceutical market in the world, currently valued at approximately US$76bn. Using BMI's...

2008-09-19 09:00:41

Research and Markets (http://www.researchandmarkets.com/research/a4c187/romania_pharmaceut) has announced the addition of the "Romania Pharmaceuticals and Healthcare Report Q3 2008" report to their offering. Our Romania Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Romania's pharmaceuticals and healthcare industry. In our adjusted Business Environment Rankings for Central & Eastern Europe (CEE) for Q308, Romania is found in...

2008-09-17 18:00:07

By The Associated Press WASHINGTON - The government is closing U.S. borders to more than 30 generic drugs - including popular antibiotics and cholesterol medicines - made by India's drug giant Ranbaxy Laboratories because of poor quality in two of its factories. The Food and Drug Administration says consumers who already have the drugs shouldn't worry: Repeated testing hasn't found any contamination, and Ranbaxy can continue selling medicines made at any of its other factories. The...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related